Brief: Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™
11/07/2025 11:06
July 11 (Reuters) - Milestone Pharmaceuticals Inc MIST.O: MILESTONE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE COMPANY’S RESPONSE TO THE CRL FOR CARDAMYST™ (ETRIPAMIL) NASAL SPRAY MILESTONE PHARMACEUTICALS INC - FDA ASSIGNS PDUFA ACTION DATE OF DECEMBER 13, 2025 MILESTONE PHARMACEUTICALS INC - EXTENDS $75 MILLION ROYALTY AGREEMENT WITH RTW UNTIL 2025 MILESTONE PHARMACEUTICALS INC - TRANSFERRED DUTIES OF MANUFACTURING TESTING FACILITY TO VENDORS WITH FDA INSPECTION HISTORY Source text: ID:nGNXxBz6D Further company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview